Quick Answer
Aptose Biosciences Inc. reported Research And Development Expense of $11.34 million for the year ending 2025.
- Aptose Biosciences Inc. showed a decrease of -24.9% in Research And Development Expense from 2024 to 2025.
- This data is from Aptose Biosciences Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $3.14 million | Q2 2018: $7.82 million | Q3 2018: $3.59 million | Q1 2019: $3.34 million | Q2 2019: $3.49 million | Q3 2019: $4.75 million | Q1 2020: $5.93 million | Q2 2020: $6.87 million | Q3 2020: $7.52 million | Q1 2021: $8.23 million | Q2 2021: $9.83 million | Q3 2021: $7.72 million | Q1 2022: $7.39 million | Q2 2022: $7.34 million | Q3 2022: $6.58 million | Q1 2023: $8.81 million | Q2 2023: $10.58 million | Q3 2023: $8.26 million | Q1 2024: $6.45 million | Q2 2024: $4.41 million | Q3 2024: $4.70 million | Q1 2025: $2.36 million | Q2 2025: $3.30 million | Q3 2025: $2.21 million.
- Over the full 9 years of available data (2017 to 2025), Aptose Biosciences Inc.'s Research And Development Expense has grown by 80.8%.
- Historical annual values: Fiscal year 2025: $11.34 million | Fiscal year 2024: $15.10 million | Fiscal year 2023: $33.27 million | Fiscal year 2022: $24.53 million | Fiscal year 2021: $45.99 million | Fiscal year 2020: $29.29 million | Fiscal year 2019: $16.84 million | Fiscal year 2018: $18.73 million | Fiscal year 2017: $6.27 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: